+91-8668442535

Nuclear Medicine/ Radiopharmaceuticals Market By Type (Diagnostics Radiopharmaceuticals, PET Radiopharmaceuticals), By Application (Therapeutic, Diagnostic Application) - Growth, Future Prospects And Competitive Analysis, 2017 - 2025

Nuclear medicine and radiopharmaceuticals are agents used to diagnose certain medical problems or treat certain diseases. Increasing awareness of radiopharmaceuticals, the growing number of pharmaceutical companies, and rising research institutes are major factors assisting the growth of the nuclear medicine and radiopharmaceuticals market globally.

The report titled "Nuclear Medicine and Radiopharmaceuticals Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall radiopharmaceuticals market, along with 

market size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on type (diagnostic and therapeutic radiopharmaceuticals), application (diagnostics, diagnostic applications), and different geographical regions.

Geographically, the global nuclear medicine and radiopharmaceuticals market is studied for the following regional markets:

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • Germany
  • Rest of Europe

Asia-Pacific

  • China
  • Japan
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of LATAM

Middle East and Africa

  • GCC
  • the remainder of MEA

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global nuclear medicine and radiopharmaceutical markets.

Tools such as market positioning of key players and appealing investment propositions provide the reader with insights into the global nuclear medicine and radiopharmaceuticals market's competitive scenario. This report concludes with a company profiles section that highlights major information about the key players engaged in the global nuclear medicine and radiopharmaceuticals market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.Thus, the research study provides a holistic view of the global radiopharmaceuticals market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Based on type, the global nuclear medicine and radiopharmaceuticals market is segmented as follows:

  • Diagnostics radiopharmaceuticals
  • SPECT Radiopharmaceuticals
  • Iodine-123
  • Technetium-99m
  • Xenon-133
  • Thallium-201
  • Fluorine-18
  • Gallium-67
  • Other SPECT Isotopes
  • PET Radiopharmaceuticals
  • Rubidium 82
  • Fluorine 18
  • Other PET radiopharmaceuticals
  • Therapeutic Radiopharmaceutical
  • Beta Emitters
  • Phosphorus 32
  • Iodine 131
  • Strontium 89
  • Yttrium 90 
  • Samarium 153
  • Rhenium 186/188 
  • Lutetium-177
  • Other beta emitters
  • Alpha Emitter
  • Radium 223 
  • Bismuth 213
  • Other beta emitters
  • Brachytherapy
  • Iridium -192
  • Palladium-103
  • Iodine-125
  • Cesium-131

Radiopharmaceuticals are unique medicinal formulations containing radioactive substances or radioactive drugs that are used for diagnosis and therapeutic interventions. It is observed that, in the base year 2016, diagnostic radiopharmaceuticals were the major revenue-generating segment due to the rising incidence of cancer and cardiac disease. Improved affordability, more precise techniques, and advancements in PET and SPECT scanning are prime factors driving the growth of the radiopharmaceutical market. Due to the increased sensitivity, improved image quality, shorter scan times, and potential to do multiple scans, PET radiopharmaceuticals are expected to show significant market growth during the forecast period.

Based on application, the global nuclear medicine and radiopharmaceuticals market is segmented as follows:

Therapeutic

  • Thyroid
  • Oncology
  • Bone Metastasis
  • Other Applications

Diagnostics

  • Cardiology
  • Thyroid
  • Oncology
  • Other Therapeutic Applications

A radiopharmaceutical is a radioactive pharmaceutical agent that is used for diagnostic or therapeutic procedures, depending on its physicochemical and radiation properties. The application of radiopharmaceuticals is categorized into two major areas: diagnostic and therapeutic. It is estimated that therapeutic applications will show the fastest market growth during the forecast period due to their advantages over traditional drug therapies, such as targeted therapeutic action and fewer side effects. Radiopharmaceuticals' application in cardiology and oncology is anticipated to grow significantly during the forecast period due to their increasing applicability in the diagnosis of diseases; furthermore, the growing prevalence of different forms of cancer and cardiovascular disease will fuel market growth. However, stringent regulatory guidelines regarding the manufacturing of radiopharmaceuticals may negatively impact the market growth of these drugs.

For the purpose of this study, the nuclear medicine and radiopharmaceuticals market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

It is observed that in the base year 2016, North America was the largest revenue contributor in the global nuclear medicine and radiopharmaceuticals market; the market's growth is mainly driven by the United States. Technological advancement, higher investment in R&D activities, the presence of key manufacturers, and the presence of a large number of research institutes are major factors that are driving the radiopharmaceuticals market in North America. However, Asia Pacific is expected to show lucrative growth during the forecast period due to the increasing partnership of key players with local manufacturers, the growing incidence and mortality of severe diseases, the growing number of geriatric populations, and the rapidly expanding pharmaceutical industries in this region. Emerging Asian countries such as China and India are expected to exhibit the highest market growth due to their developing economic conditions and the growing partnership of key players with local manufacturers.

Frequently Asked Questions:

The market for Nuclear Medicine/ Radiopharmaceuticals Market is expected to reach US$ 7.78 Bn By 2025.

The Nuclear Medicine/ Radiopharmaceuticals Market is expected to see significant CAGR growth over the coming years, at 5.5%.

The report is forecasted from 2017-2025.

The base year of this report is 2016.

Advanced Accelerator Applications S.A., Bracco Imaging S.p.A, Cardinal Health, Inc., Lantheus Medical Imaging Inc.are some of the major players in the global market.

 

 

Choose License Type
Trusted By
Godaddy
Published Date:  Oct 2017
Category:  Pharmaceuticals
Report ID:   58722
Report Format:   PDF
Pages:   120
Rating:    4.8 (80)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support